Mulhouse, France

Patrick Chène

This inventor holds 2 USPTO granted patents and 8 published patent applications and 2 EPO patents. Top assignees: Cancer Research Campaign Technology Limited, Novartis Ag. Active years: 2006-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Patrick Chène. Retrieved from https://idiyas.com/inventor/patrick-chene

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 10.7

ph-index = 1

Forward Citations = 79(Granted Patents)


Company Filing History:


Years Active: 2006-2024

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Patrick Chene

Introduction

Patrick Chene is an accomplished inventor based in Mulhouse, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit protein-protein interactions.

Latest Patents

Chene holds a patent for "Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors." This invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, showcasing his innovative approach to addressing complex biological interactions.

Career Highlights

Throughout his career, Patrick Chene has worked with notable companies such as Novartis AG and Vernalis Limited. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Chene has collaborated with talented individuals in his field, including Vincent Bordas and Cara Brocklehurst. These partnerships have further enhanced his work and led to advancements in his research endeavors.

Conclusion

Patrick Chene's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to influence the development of new therapeutic strategies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…